Intestinal Microbiota Profiling in Severe Acute Alcoholic Hepatitis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-15

Study Completion Date

2028-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In humans, alcohol-related dysbiosis exists with a decrease in bacteroides. This dysbiosis is responsible for the breakdown of the intestinal barrier by a decrease in the synthesis of protective mucus, and some proteins involved in tight junctions or a decrease in defensin (Reg3b, Reg3g) which promotes bacterial growth and ultimately bacterial translocation. The microbiota of a patient with alcoholic hepatitis is different from that of a patient without alcoholic hepatitis. Acute alcoholic hepatitis has a severe prognosis and corticosteroids are the only first line therapy option, with better survival at 28 days versus placebo. However, mortality remains high at 30% at 3 months, which highlights the importance of seeking intestinal microbiota profile on treatment response.

The determination of one or more intestinal microbiota signatures associated with the treatment response Corticosteroids plus FMT or Corticosteroids plus placebo will allow the clinician to have a simple and rapid test obtained in 16S RNA analysis to predict the therapeutic response and potentially the best treatment to adopt and to address medical and medico-economic stakes.

The investigators will first characterize the alcohol-induced dysbiosis by a whole microbiota sequencing in the different groups. Specific bacterial species identify by DNA sequencing should be confirmed by qPCR of 16S rDNA to determine a fingerprint of sAH microbiota. Metabolic properties of intestinal microbiota, such as production of short chain fatty acids, will be analyzed by using HPLC. In the sAH group, evolution of intestinal microbiota will be observed by shotgun DNA sequencing between the day 0 and the day 7 of corticosteroids treatment.

The analysis of sAH patients' microbiota (day 0) will allow us to obtain a non-responder profile to corticosteroids that can be used as a prognostic marker to use in the clinic. The deliverable is the bacterial fingerprint of the treatment response and its valuation is its use as a predictive tool of the response.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Utility of Handheld Hydrogen Breathalyzer in Identification of Food Sensitivities (AIRE Study)

NCT04309396

SIBO Small Bowel Bacterial Overgrowth Syndrome

COMPLETED NA

Elemental Diet and Gut Microbiome

NCT05978973

Irritable Bowel Syndrome

COMPLETED NA

The Effect of Dietary Intervention on Symptoms, Epigenetics, and Gut Microbiota in IBS

NCT03306381

IBS - Irritable Bowel Syndrome

COMPLETED NA

Assessment of Small Intestinal Bowel Epithelial Gaps in Irritable Bowel Syndrome

NCT01632488

Irritable Bowel Syndrome Inflammatory Bowel Disease

UNKNOWN

Gut Microbiome in Inflammatory Bowel Disease

NCT03589183

Inflammatory Bowel Diseases Ulcerative Colitis Crohn Disease

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Acute Alcoholic Hepatitis Alcohol Intestinal Microbiota Corticosteroids

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

sAH patients

the recruitment of patients with sAH will be carried out from the Hepatogastroenterology Service of the University Hospital of Amiens.

Group Type EXPERIMENTAL

stool withdrawal

Intervention Type OTHER

stool withdrawal at day 0 and day 7

Alcohol controls without liver complications

the recruitment of alcohol controls will concern patients followed for alcohol addiction without sAH in the antecedents or evolutionary. It will be carried out by the Hospital of Roye-Montdidier. The total number of controls will be equivalent to the number of sAH patients, matched for age and sex.

Group Type EXPERIMENTAL

stool withdrawal

Intervention Type OTHER

stool withdrawal at day 0 and day 7

Healthy non-alcoholic witnesses

the general population will be called with a matching on age

Group Type ACTIVE_COMPARATOR

stool withdrawal

Intervention Type OTHER

stool withdrawal at day 0 and day 7

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

stool withdrawal

stool withdrawal at day 0 and day 7

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged from 18 to 75 years, having :
* Heavy drinker with Maddrey Score ≥ 32 : PT(second)-PT(control)x4.6+Bilirubine (mg/dl)
* Histological confirmed Alcoholic hepatitis
* Personal consent signed to the trial

Exclusion Criteria

* Age \< 18 years and/or \> 75 years,
* Pregnancy or lactating females,
* No personal consent
* Other causes of liver disease: chronic hepatitis B (antigen HBs positive), hepatitis C (HCV RNA positive), acetaminophen hepatotoxicity, biliary obstruction, autoimmune hepatitis, primary biliary cholangitis, primary sclerosis cholangitis, alpha 1 antitrypsine deficiency, and Wilson disease.
* Uncontrolled liver complications:
* Upper gastrointestinal bleed by portal hypertension (4 days required for stable condition)
* Active sepsis (4 days required for stable condition)
* Patient currently treated by antibiotic
* Concomitant Liver cancer (HCC) or extrahepatic malignancy
* Type 1 hepatorenal syndrome (HRS) or renal failure defined as a serum creatinine \>221 μmol/L (\>2.5 mg/dL) or the requirement for renal replacement therapy
* Grade 4 Hepatic Encephalopathy (HE) by West Haven criteria
* Individuals dependent on inotropic (eg, epinephrine or norepinephrine) or ventilatory support (ie, endotracheal intubation or positive-pressure ventilation)
* Disseminated intravascular coagulation
* Intestinal paralysis
* History of liver transplantation

Other general diseases or severe conditions:

* HIV disease
* Intestinal paralysis
* Intestinal inflammatory disease (Crohn or Ulcerative colitis)
* Clostridium difficilae infection
* Clinical suspicion of pneumonia
* Uncontrolled sepsis
* Acute Alcoholic pancreatitis
* Noncontrolled alcohol withdrawal syndrome
* Cardiac or respiratory bad conditions

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes